30 November 2009

Executive Director’s Presentation to the 2009 Annual General Meeting

25 June 2009

Investor Presentation to Australian Institutional Investors and Fund Managers. Executive Director Professor Silviu Itescu

27 November 2008

Executive Director's Presentation at the AGM

21 November 2007

Presentation to the AGM by Chief Scientific Adviser

23 November 2006

Presentation to the AGM/EGM by Chief Scientific Adviser

15 November 2006

AGM Presentation-Today’s Commercial & Clinical Reality

19 October 2005

'Today's Clinical Reality' - Presentation to the 5th Annual Stem Cells & Regenerative Medicine Conference in Pittsburgh, United States.

13 October 2005

MESOBLAST – INVESTOR UPDATE PRESENTATION: Australian adult stem cell company, Mesoblast Limited (ASX: MSB), today provided a presentation update.

Key points in the presentation to the investment community by Mesoblast’s Executive Chairman, Mr Michael Spooner, include:

27 July 2005

Presentation by Mesoblast Founder and Chief Scientific Adviser, Professor Silviu Itescu, to members of the investment community and to the Australian Biotechnology Summit in Sydney on 26 July, where he was a keynote speaker.

31 March 2005

INVESTOR PRESENTATION : Presentation by Mesoblast Founder and Chief Scientific Adviser, Professor Silviu Itescu, to institutional fund managers at Lodge Partners' small and mid-cap conference in Victoria on 31 March 2005.

14 January 2005

Mesoblast Presentation 1

 

Investor Centre

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine